Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BPDCN

- PMLiVE

Pfizer’s Talzenna recommended by NICE for advanced breast cancer

An estimated 300 patients will be eligible for treatment with the PARP inhibitor

icons related to iconography inside Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why iconography matters…

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy + Cuttsy

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

- PMLiVE

Pfizer’s Talzenna combination receives EC approval for metastatic prostate cancer

Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Impetus Digital

- PMLiVE

Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed each year in Europe

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...

Impetus Digital

- PMLiVE

First WHO Global Clinical Trial Forum develops joint vision to improve clinical research

Experts in areas including cancer, AMR and neurological diseases participated

- PMLiVE

Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults

RSV is associated with 15,000 hospital admissions in infants under six months every year in England

- PMLiVE

FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies

The regulator will monitor approved BCMA- or CD19-directed autologous CAR-T cell immunotherapies

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.

Impetus Digital

- PMLiVE

UK government and NIHR accelerate plans to improve clinical research delivery

The government has created a focused plan for action to transform UK clinical research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links